INDV Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Indivior Pharmaceuticals, Inc (INDV) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The company's strong financial growth, positive analyst ratings, and undervaluation relative to fundamentals make it a compelling long-term opportunity despite the lack of immediate trading signals.
The MACD is positive and expanding, indicating bullish momentum. RSI is neutral at 54.976, suggesting no overbought or oversold conditions. Moving averages are converging, signaling potential consolidation. Key support is at 28.181, and resistance is at 30.912, with the stock trading near resistance levels.
Analyst upgrade with a price target increase to $50, citing undervaluation and improving fundamentals.
SUBLOCADE® adoption in prisons demonstrates cost-saving benefits, potentially driving revenue growth.
Strong financial performance in Q3 2025, with significant YoY growth in net income and EPS.
Gross margin decline by 6.28% YoY, which may indicate rising costs or pricing pressures.
Lack of recent trading activity or signals from hedge funds, insiders, or Congress.
In Q3 2025, revenue increased by 2.28% YoY to $314 million. Net income surged by 90.91% YoY to $42 million, and EPS grew by 94.12% YoY to 0.33. However, gross margin dropped to 73.57%, down 6.28% YoY.
Northland raised the price target from $40 to $50 and maintained an Outperform rating, citing undervaluation and improved capital allocation options. Analysts view the stock as disconnected from its strong underlying fundamentals.
